ANA as an entry criterion for the classification of SLE.

Journal Article (Journal Article;Review)

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease with highly variable clinical and immunological manifestations. In the classification of patients with this condition, the presence of an antinuclear antibody (ANA) is an important element, with new criteria from the American College of Rheumatology and European League against Rheumatism positioning ANA positivity by an immunofluorescence assay on HEp2-cells (HEp2-IFA) or by an equivalent solid phase assay as the entry criterion. This positioning is based on assumptions about the frequency of ANA positivity in SLE as well as the reliability of the assays. Studies indicate that these assumptions are still a matter of uncertainty since both types of assay show considerable variability and patients with SLE may display negative results in ANA testing. These findings suggest caution in positioning ANA positivity as an entry criterion for classification and point to the value of alternative serological approaches for ANA determinations.

Full Text

Duke Authors

Cited Authors

  • Pisetsky, DS; Bossuyt, X; Meroni, PL

Published Date

  • December 2019

Published In

Volume / Issue

  • 18 / 12

Start / End Page

  • 102400 -

PubMed ID

  • 31639513

Electronic International Standard Serial Number (EISSN)

  • 1873-0183

Digital Object Identifier (DOI)

  • 10.1016/j.autrev.2019.102400


  • eng

Conference Location

  • Netherlands